<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;ff=20240628021302
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;ff=20240628021302" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 28 Jun 2024 06:13:03 +0000</lastbuilddate>
<pubDate>Thu, 27 Jun 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Preclinical proof of principle for orally delivered Th17 antagonist miniproteins</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38936360/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>Interleukin (IL)-23 and IL-17 are well-validated therapeutic targets in autoinflammatory diseases. Antibodies targeting IL-23 and IL-17 have shown clinical efficacy but are limited by high costs, safety risks, lack of sustained efficacy, and poor patient convenience as they require parenteral administration. Here, we present designed miniproteins inhibiting IL-23R and IL-17 with antibody-like, low picomolar affinities at a fraction of the molecular size. The minibinders potently block cell...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 23:S0092-8674(24)00631-7. doi: 10.1016/j.cell.2024.05.052. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Interleukin (IL)-23 and IL-17 are well-validated therapeutic targets in autoinflammatory diseases. Antibodies targeting IL-23 and IL-17 have shown clinical efficacy but are limited by high costs, safety risks, lack of sustained efficacy, and poor patient convenience as they require parenteral administration. Here, we present designed miniproteins inhibiting IL-23R and IL-17 with antibody-like, low picomolar affinities at a fraction of the molecular size. The minibinders potently block cell signaling in vitro and are extremely stable, enabling oral administration and low-cost manufacturing. The orally administered IL-23R minibinder shows efficacy better than a clinical anti-IL-23 antibody in mouse colitis and has a favorable pharmacokinetics (PK) and biodistribution profile in rats. This work demonstrates that orally administered de novo-designed minibinders can reach a therapeutic target past the gut epithelial barrier. With high potency, gut stability, and straightforward manufacturability, de novo-designed minibinders are a promising modality for oral biologics.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38936360/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38936360</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.052>10.1016/j.cell.2024.05.052</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38936360</guid>
<pubDate>Thu, 27 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Stephanie Berger</dc:creator>
<dc:creator>Franziska Seeger</dc:creator>
<dc:creator>Ta-Yi Yu</dc:creator>
<dc:creator>Merve Aydin</dc:creator>
<dc:creator>Huilin Yang</dc:creator>
<dc:creator>Daniel Rosenblum</dc:creator>
<dc:creator>Laure Guenin-Macé</dc:creator>
<dc:creator>Caleb Glassman</dc:creator>
<dc:creator>Lauren Arguinchona</dc:creator>
<dc:creator>Catherine Sniezek</dc:creator>
<dc:creator>Alyssa Blackstone</dc:creator>
<dc:creator>Lauren Carter</dc:creator>
<dc:creator>Rashmi Ravichandran</dc:creator>
<dc:creator>Maggie Ahlrichs</dc:creator>
<dc:creator>Michael Murphy</dc:creator>
<dc:creator>Ingrid Swanson Pultz</dc:creator>
<dc:creator>Alex Kang</dc:creator>
<dc:creator>Asim K Bera</dc:creator>
<dc:creator>Lance Stewart</dc:creator>
<dc:creator>K Christopher Garcia</dc:creator>
<dc:creator>Shruti Naik</dc:creator>
<dc:creator>Jamie B Spangler</dc:creator>
<dc:creator>Florian Beigel</dc:creator>
<dc:creator>Matthias Siebeck</dc:creator>
<dc:creator>Roswitha Gropp</dc:creator>
<dc:creator>David Baker</dc:creator>
<dc:date>2024-06-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Preclinical proof of principle for orally delivered Th17 antagonist miniproteins</dc:title>
<dc:identifier>pmid:38936360</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.052</dc:identifier>
</item>
<item>
<title>Amplification editing enables efficient and precise duplication of DNA from short sequence to megabase and chromosomal scale</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38936359/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>Duplication is a foundation of molecular evolution and a driver of genomic and complex diseases. Here, we develop a genome editing tool named Amplification Editing (AE) that enables programmable DNA duplication with precision at chromosomal scale. AE can duplicate human genomes ranging from 20 bp to 100 Mb, a size comparable to human chromosomes. AE exhibits activity across various cell types, encompassing diploid, haploid, and primary cells. AE exhibited up to 73.0% efficiency for 1 Mb and 3.4%...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 19:S0092-8674(24)00637-8. doi: 10.1016/j.cell.2024.05.056. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Duplication is a foundation of molecular evolution and a driver of genomic and complex diseases. Here, we develop a genome editing tool named Amplification Editing (AE) that enables programmable DNA duplication with precision at chromosomal scale. AE can duplicate human genomes ranging from 20 bp to 100 Mb, a size comparable to human chromosomes. AE exhibits activity across various cell types, encompassing diploid, haploid, and primary cells. AE exhibited up to 73.0% efficiency for 1 Mb and 3.4% for 100 Mb duplications, respectively. Whole-genome sequencing and deep sequencing of the junctions of edited sequences confirm the precision of duplication. AE can create chromosomal microduplications within disease-relevant regions in embryonic stem cells, indicating its potential for generating cellular and animal models. AE is a precise and efficient tool for chromosomal engineering and DNA duplication, broadening the landscape of precision genome editing from an individual genetic locus to the chromosomal scale.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38936359/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38936359</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.056>10.1016/j.cell.2024.05.056</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38936359</guid>
<pubDate>Thu, 27 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Ruiwen Zhang</dc:creator>
<dc:creator>Zhou He</dc:creator>
<dc:creator>Yajing Shi</dc:creator>
<dc:creator>Xiangkun Sun</dc:creator>
<dc:creator>Xinyu Chen</dc:creator>
<dc:creator>Guoquan Wang</dc:creator>
<dc:creator>Yizhou Zhang</dc:creator>
<dc:creator>Pan Gao</dc:creator>
<dc:creator>Ying Wu</dc:creator>
<dc:creator>Shuhan Lu</dc:creator>
<dc:creator>Junyi Duan</dc:creator>
<dc:creator>Shangwu Sun</dc:creator>
<dc:creator>Na Yang</dc:creator>
<dc:creator>Wei Fan</dc:creator>
<dc:creator>Kaitao Zhao</dc:creator>
<dc:creator>Bei Yang</dc:creator>
<dc:creator>Yuchen Xia</dc:creator>
<dc:creator>Yan Zhang</dc:creator>
<dc:creator>Ying Zhang</dc:creator>
<dc:creator>Hao Yin</dc:creator>
<dc:date>2024-06-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Amplification editing enables efficient and precise duplication of DNA from short sequence to megabase and chromosomal scale</dc:title>
<dc:identifier>pmid:38936359</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.056</dc:identifier>
</item>
<item>
<title>Transcatheter treatment of pure aortic regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38937627/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jun 27. doi: 10.1038/s41569-024-01059-1. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38937627/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38937627</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01059-1>10.1038/s41569-024-01059-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38937627</guid>
<pubDate>Thu, 27 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Marco Barbanti</dc:creator>
<dc:creator>Giulia Laterra</dc:creator>
<dc:creator>Francesco Maisano</dc:creator>
<dc:date>2024-06-27</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Transcatheter treatment of pure aortic regurgitation</dc:title>
<dc:identifier>pmid:38937627</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01059-1</dc:identifier>
</item>
<item>
<title>Autoimmune diseases and atherosclerotic cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38937626/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>Autoimmune diseases are associated with a dramatically increased risk of atherosclerotic cardiovascular disease and its clinical manifestations. The increased risk is consistent with the notion that atherogenesis is modulated by both protective and disease-promoting immune mechanisms. Notably, traditional cardiovascular risk factors such as dyslipidaemia and hypertension alone do not explain the increased risk of cardiovascular disease associated with autoimmune diseases. Several mechanisms have...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jun 27. doi: 10.1038/s41569-024-01045-7. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Autoimmune diseases are associated with a dramatically increased risk of atherosclerotic cardiovascular disease and its clinical manifestations. The increased risk is consistent with the notion that atherogenesis is modulated by both protective and disease-promoting immune mechanisms. Notably, traditional cardiovascular risk factors such as dyslipidaemia and hypertension alone do not explain the increased risk of cardiovascular disease associated with autoimmune diseases. Several mechanisms have been implicated in mediating the autoimmunity-associated cardiovascular risk, either directly or by modulating the effect of other risk factors in a complex interplay. Aberrant leukocyte function and pro-inflammatory cytokines are central to both disease entities, resulting in vascular dysfunction, impaired resolution of inflammation and promotion of chronic inflammation. Similarly, loss of tolerance to self-antigens and the generation of autoantibodies are key features of autoimmunity but are also implicated in the maladaptive inflammatory response during atherosclerotic cardiovascular disease. Therefore, immunomodulatory therapies are potential efficacious interventions to directly reduce the risk of cardiovascular disease, and biomarkers of autoimmune disease activity could be relevant tools to stratify patients with autoimmunity according to their cardiovascular risk. In this Review, we discuss the pathophysiological aspects of the increased cardiovascular risk associated with autoimmunity and highlight the many open questions that need to be answered to develop novel therapies that specifically address this unmet clinical need.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38937626/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38937626</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01045-7>10.1038/s41569-024-01045-7</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38937626</guid>
<pubDate>Thu, 27 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Florentina Porsch</dc:creator>
<dc:creator>Christoph J Binder</dc:creator>
<dc:date>2024-06-27</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Autoimmune diseases and atherosclerotic cardiovascular disease</dc:title>
<dc:identifier>pmid:38937626</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01045-7</dc:identifier>
</item>
<item>
<title>Great debate: device-detected subclinical atrial fibrillation should be treated like clinical atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38935554/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 27:ehae365. doi: 10.1093/eurheartj/ehae365. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38935554/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38935554</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae365>10.1093/eurheartj/ehae365</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38935554</guid>
<pubDate>Thu, 27 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Prashanthan Sanders</dc:creator>
<dc:creator>Emma Svennberg</dc:creator>
<dc:creator>Søren Z Diederichsen</dc:creator>
<dc:creator>Harry J G M Crijns</dc:creator>
<dc:creator>Pier D Lambiase</dc:creator>
<dc:creator>Giuseppe Boriani</dc:creator>
<dc:creator>Isabelle C Van Gelder</dc:creator>
<dc:date>2024-06-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Great debate: device-detected subclinical atrial fibrillation should be treated like clinical atrial fibrillation</dc:title>
<dc:identifier>pmid:38935554</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae365</dc:identifier>
</item>
<item>
<title>Associations of Urban Blue and Green Spaces With Coronary Artery Calcification in Black Individuals and Disadvantaged Neighborhoods</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38934130/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Longitudinally, shorter distance to a river and greater green space cover were associated with less CAC among Black participants and those in deprived neighborhoods. Shorter distance to a park was associated with increased odds of CAC among participants in deprived neighborhoods. Black participants residing in more deprived neighborhoods showed lower odds of CAC in association with greater exposure to river and green space cover.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 27. doi: 10.1161/CIRCULATIONAHA.123.067992. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Proximity to urban blue and green spaces has been associated with improved cardiovascular health; however, few studies have examined the role of race and socioeconomic status in these associations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Data were from the CARDIA study (Coronary Artery Risk Development in Young Adults). We included longitudinal measurements (1985-1986 to 2010-2011) of blue and green spaces, including percentage of blue space cover, distance to the nearest river, green space cover, and distance to the nearest major park. Presence of coronary artery calcification (CAC) was measured with noncontrast cardiac computed tomography in 2010 to 2011. The associations of blue and green spaces with CAC were assessed with generalized estimating equation regression with adjustment for demographics, individual and neighborhood socioeconomic status, health-related behaviors, and other health conditions. We conducted stratified analyses by race and neighborhood deprivation score to investigate whether the association varied according to social determinants of health.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The analytic sample included 1365 Black and 1555 White participants with a mean±SD age of 50.1±3.6 years. Among Black participants, shorter distance to a river and greater green space cover were associated with lower odds of CAC (per interquartile range decrease [1.45 km] to the river: odds ratio [OR], 0.90 [95% CI, 0.84-0.96]; per 10%-point increase of green space cover: OR, 0.85 [95% CI, 0.75-0.95]). Among participants in deprived neighborhoods, greater green space cover was associated with lower odds of CAC (per a 10%-point increase: OR, 0.89 [95% CI, 0.80-0.99]), whereas shorter distance to the park was associated with higher odds of CAC (per an interquartile range decrease [5.3 km]: OR, 1.07 [95% CI, 1.00-1.15]). Black participants in deprived neighborhoods had lower odds of CAC with shorter distance to a river (per an interquartile range decrease: OR, 0.90 [95% CI, 0.82-0.98]) and greater green space cover (per a 10%-point increase: OR, 0.85 [95% CI, 0.75-0.97]). There was no statistical interaction between the blue and green spaces and race or neighborhood characteristics in association with CAC.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Longitudinally, shorter distance to a river and greater green space cover were associated with less CAC among Black participants and those in deprived neighborhoods. Shorter distance to a park was associated with increased odds of CAC among participants in deprived neighborhoods. Black participants residing in more deprived neighborhoods showed lower odds of CAC in association with greater exposure to river and green space cover.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38934130/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38934130</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067992>10.1161/CIRCULATIONAHA.123.067992</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38934130</guid>
<pubDate>Thu, 27 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Kyeezu Kim</dc:creator>
<dc:creator>Brian T Joyce</dc:creator>
<dc:creator>Yinan Zheng</dc:creator>
<dc:creator>Drew R Nannini</dc:creator>
<dc:creator>Jun Wang</dc:creator>
<dc:creator>Penny Gordon-Larsen</dc:creator>
<dc:creator>Ankeet Bhatt</dc:creator>
<dc:creator>Kelley Gabriel</dc:creator>
<dc:creator>James M Shikany</dc:creator>
<dc:creator>Ming Hu</dc:creator>
<dc:creator>Aimin Chen</dc:creator>
<dc:creator>Orna Reges</dc:creator>
<dc:creator>Mercedes R Carnethon</dc:creator>
<dc:creator>Donald M Lloyd-Jones</dc:creator>
<dc:creator>Kai Zhang</dc:creator>
<dc:creator>Lifang Hou</dc:creator>
<dc:date>2024-06-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Associations of Urban Blue and Green Spaces With Coronary Artery Calcification in Black Individuals and Disadvantaged Neighborhoods</dc:title>
<dc:identifier>pmid:38934130</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067992</dc:identifier>
</item>
<item>
<title>Improving Outcomes After Post-Cardiac Arrest Brain Injury: A Scientific Statement From the International Liaison Committee on Resuscitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38934122/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>This scientific statement presents a conceptual framework for the pathophysiology of post-cardiac arrest brain injury, explores reasons for previous failure to translate preclinical data to clinical practice, and outlines potential paths forward. Post-cardiac arrest brain injury is characterized by 4 distinct but overlapping phases: ischemic depolarization, reperfusion repolarization, dysregulation, and recovery and repair. Previous research has been challenging because of the limitations of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 27. doi: 10.1161/CIR.0000000000001219. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This scientific statement presents a conceptual framework for the pathophysiology of post-cardiac arrest brain injury, explores reasons for previous failure to translate preclinical data to clinical practice, and outlines potential paths forward. Post-cardiac arrest brain injury is characterized by 4 distinct but overlapping phases: ischemic depolarization, reperfusion repolarization, dysregulation, and recovery and repair. Previous research has been challenging because of the limitations of laboratory models; heterogeneity in the patient populations enrolled; overoptimistic estimation of treatment effects leading to suboptimal sample sizes; timing and route of intervention delivery; limited or absent evidence that the intervention has engaged the mechanistic target; and heterogeneity in postresuscitation care, prognostication, and withdrawal of life-sustaining treatments. Future trials must tailor their interventions to the subset of patients most likely to benefit and deliver this intervention at the appropriate time, through the appropriate route, and at the appropriate dose. The complexity of post-cardiac arrest brain injury suggests that monotherapies are unlikely to be as successful as multimodal neuroprotective therapies. Biomarkers should be developed to identify patients with the targeted mechanism of injury, to quantify its severity, and to measure the response to therapy. Studies need to be adequately powered to detect effect sizes that are realistic and meaningful to patients, their families, and clinicians. Study designs should be optimized to accelerate the evaluation of the most promising interventions. Multidisciplinary and international collaboration will be essential to realize the goal of developing effective therapies for post-cardiac arrest brain injury.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38934122/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38934122</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001219>10.1161/CIR.0000000000001219</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38934122</guid>
<pubDate>Thu, 27 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Gavin D Perkins</dc:creator>
<dc:creator>Robert Neumar</dc:creator>
<dc:creator>Cindy H Hsu</dc:creator>
<dc:creator>Karen G Hirsch</dc:creator>
<dc:creator>Anders Aneman</dc:creator>
<dc:creator>Lance B Becker</dc:creator>
<dc:creator>Keith Couper</dc:creator>
<dc:creator>Clifton W Callaway</dc:creator>
<dc:creator>Cornelia W E Hoedemaekers</dc:creator>
<dc:creator>Shir Lynn Lim</dc:creator>
<dc:creator>William Meurer</dc:creator>
<dc:creator>Theresa Olasveengen</dc:creator>
<dc:creator>Mypinder S Sekhon</dc:creator>
<dc:creator>Markus Skrifvars</dc:creator>
<dc:creator>Jasmeet Soar</dc:creator>
<dc:creator>Min-Shan Tsai</dc:creator>
<dc:creator>Bhuma Vengamma</dc:creator>
<dc:creator>Jerry P Nolan</dc:creator>
<dc:creator>International Liaison Committee on Resuscitation</dc:creator>
<dc:date>2024-06-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Improving Outcomes After Post-Cardiac Arrest Brain Injury: A Scientific Statement From the International Liaison Committee on Resuscitation</dc:title>
<dc:identifier>pmid:38934122</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001219</dc:identifier>
</item>
<item>
<title>Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38934111/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The COORDINATE-Diabetes intervention successfully improved delivery of evidence-based care, regardless of sex, race, or ethnicity. Widespread dissemination of this intervention could improve equitable health care quality, particularly among women and minority communities who are frequently underrepresented in clinical trials.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 27. doi: 10.1161/CIRCULATIONAHA.124.068962. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Results from the COORDINATE-Diabetes trial demonstrated that a multifaceted, clinic-based intervention increased prescription of evidence-based medical therapies to participants with type 2 diabetes and atherosclerotic cardiovascular disease. This secondary analysis assessed whether intervention success was consistent across sex, race, and ethnicity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: COORDINATE-Diabetes, a cluster randomized trial, recruited participants from 43 US cardiology clinics (20 randomized to intervention and 23 randomized to usual care). The primary outcome was the proportion of participants prescribed all 3 groups of evidence-based therapy (high-intensity statin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, and sodium-glucose cotransporter-2 inhibitor or glucagon-like peptide 1 receptor agonist) at last trial assessment (6 to 12 months). In this prespecified analysis, mixed-effects logistic regression models were used to assess the outcome by self-reported sex, race, and ethnicity in the intervention and usual care groups, with adjustment for baseline characteristics, medications, comorbidities, and site location.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 1045 participants with type 2 diabetes and atherosclerotic cardiovascular disease, the median age was 70 years, 32% were female, 16% were Black, and 9% were Hispanic. At the last trial assessment, there was an absolute increase in the proportion of participants prescribed all 3 groups of evidence-based therapy in women (36% versus 15%), Black participants (41% versus 18%), and Hispanic participants (46% versus 18%) with the intervention compared with usual care, with consistent benefit across sex (male versus female; <i>P</i><sub>interaction</sub>=0.44), race (Black versus White; <i>P</i><sub>interaction</sub>=0.59), and ethnicity (Hispanic versus Non-Hispanic; <i>P</i><sub>interaction</sub>= 0.78).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The COORDINATE-Diabetes intervention successfully improved delivery of evidence-based care, regardless of sex, race, or ethnicity. Widespread dissemination of this intervention could improve equitable health care quality, particularly among women and minority communities who are frequently underrepresented in clinical trials.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://clinicaltrials.gov. Unique identifier: NCT03936660.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38934111/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38934111</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068962>10.1161/CIRCULATIONAHA.124.068962</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38934111</guid>
<pubDate>Thu, 27 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Manasi Tannu</dc:creator>
<dc:creator>Lisa Kaltenbach</dc:creator>
<dc:creator>Neha J Pagidipati</dc:creator>
<dc:creator>Darren K McGuire</dc:creator>
<dc:creator>Vanita R Aroda</dc:creator>
<dc:creator>Rodica Pop-Busui</dc:creator>
<dc:creator>Nitin Kondamudi</dc:creator>
<dc:creator>Hussein R Al-Khalidi</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Matthew A Cavender</dc:creator>
<dc:creator>Adam J Nelson</dc:creator>
<dc:creator>Julienne Kirk</dc:creator>
<dc:creator>Ildiko Lingvay</dc:creator>
<dc:creator>Melissa Magwire</dc:creator>
<dc:creator>Caroline Regina Richardson</dc:creator>
<dc:creator>Laura Webb</dc:creator>
<dc:creator>Monica Leyva</dc:creator>
<dc:creator>Ambarish Pandey</dc:creator>
<dc:creator>Alana Washington</dc:creator>
<dc:creator>Jonathan Pak</dc:creator>
<dc:creator>Tanya Gaynor</dc:creator>
<dc:creator>Waqar Khan</dc:creator>
<dc:creator>Patrick Weston</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Jennifer Green</dc:creator>
<dc:date>2024-06-27</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial</dc:title>
<dc:identifier>pmid:38934111</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068962</dc:identifier>
</item>
<item>
<title>Global epidemiology of heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38926611/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>Heart failure (HF) is a heterogeneous clinical syndrome marked by substantial morbidity and mortality. The natural history of HF is well established; however, epidemiological data are continually evolving owing to demographic shifts, advances in treatment and variations in access to health care. Although the incidence of HF has stabilized or declined in high-income countries over the past decade, its prevalence continues to increase, driven by an ageing population, an increase in risk factors,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jun 26. doi: 10.1038/s41569-024-01046-6. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Heart failure (HF) is a heterogeneous clinical syndrome marked by substantial morbidity and mortality. The natural history of HF is well established; however, epidemiological data are continually evolving owing to demographic shifts, advances in treatment and variations in access to health care. Although the incidence of HF has stabilized or declined in high-income countries over the past decade, its prevalence continues to increase, driven by an ageing population, an increase in risk factors, the effectiveness of novel therapies and improved survival. This rise in prevalence is increasingly noted among younger adults and is accompanied by a shift towards HF with preserved ejection fraction. However, disparities exist in our epidemiological understanding of HF burden and progression in low-income and middle-income countries owing to the lack of comprehensive data in these regions. Therefore, the current epidemiological landscape of HF highlights the need for periodic surveillance and resource allocation tailored to geographically vulnerable areas. In this Review, we highlight global trends in the burden of HF, focusing on the variations across the spectrum of left ventricular ejection fraction. We also discuss evolving population-based estimates of HF incidence and prevalence, the risk factors for and aetiologies of this disease, and outcomes in different geographical regions and populations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38926611/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38926611</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01046-6>10.1038/s41569-024-01046-6</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38926611</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Muhammad Shahzeb Khan</dc:creator>
<dc:creator>Izza Shahid</dc:creator>
<dc:creator>Ahmed Bennis</dc:creator>
<dc:creator>Amina Rakisheva</dc:creator>
<dc:creator>Marco Metra</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Global epidemiology of heart failure</dc:title>
<dc:identifier>pmid:38926611</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01046-6</dc:identifier>
</item>
<item>
<title>Transforming Cardiovascular Care With Artificial Intelligence: From Discovery to Practice: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38925729/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>Artificial intelligence (AI) has the potential to transform every facet of cardiovascular practice and research. The exponential rise in technology powered by AI is defining new frontiers in cardiovascular care, with innovations that span novel diagnostic modalities, new digital native biomarkers of disease, and high-performing tools evaluating care quality and prognosticating clinical outcomes. These digital innovations promise expanded access to cardiovascular screening and monitoring,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 2;84(1):97-114. doi: 10.1016/j.jacc.2024.05.003.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Artificial intelligence (AI) has the potential to transform every facet of cardiovascular practice and research. The exponential rise in technology powered by AI is defining new frontiers in cardiovascular care, with innovations that span novel diagnostic modalities, new digital native biomarkers of disease, and high-performing tools evaluating care quality and prognosticating clinical outcomes. These digital innovations promise expanded access to cardiovascular screening and monitoring, especially among those without access to high-quality, specialized care historically. Moreover, AI is propelling biological and clinical discoveries that will make future cardiovascular care more personalized, precise, and effective. The review brings together these diverse AI innovations, highlighting developments in multimodal cardiovascular AI across clinical practice and biomedical discovery, and envisioning this new future backed by contemporary science and emerging discoveries. Finally, we define the critical path and the safeguards essential to realizing this AI-enabled future that helps achieve optimal cardiovascular health and outcomes for all.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38925729/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38925729</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.003>10.1016/j.jacc.2024.05.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38925729</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Rohan Khera</dc:creator>
<dc:creator>Evangelos K Oikonomou</dc:creator>
<dc:creator>Girish N Nadkarni</dc:creator>
<dc:creator>Jessica R Morley</dc:creator>
<dc:creator>Jenna Wiens</dc:creator>
<dc:creator>Atul J Butte</dc:creator>
<dc:creator>Eric J Topol</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transforming Cardiovascular Care With Artificial Intelligence: From Discovery to Practice: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:38925729</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.003</dc:identifier>
</item>
<item>
<title>Lessons for Cardiovascular Clinical Investigators: The Tumultuous 2,500-Year Journey of Physicians Who Ignited Our Fire</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38925728/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>Whereas medical practice stems from Hippocrates, cardiovascular science originates with Aristotle. The Hippocratic philosophy was championed by Galen (129-216 CE), whose advocacy of a tripartite soul found favor in the early Christian Church. In contrast, Aristotle's works were banned as heresy by ecclesiastical authority, only to survive and prosper in the Islamic Golden Age (775-1258 CE). Galen theorized that the circulation consisted of separate venous and arterial systems. Blood was produced...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 2;84(1):78-96. doi: 10.1016/j.jacc.2024.03.420.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Whereas medical practice stems from Hippocrates, cardiovascular science originates with Aristotle. The Hippocratic philosophy was championed by Galen (129-216 CE), whose advocacy of a tripartite soul found favor in the early Christian Church. In contrast, Aristotle's works were banned as heresy by ecclesiastical authority, only to survive and prosper in the Islamic Golden Age (775-1258 CE). Galen theorized that the circulation consisted of separate venous and arterial systems. Blood was produced in the liver and traveled centrifugally through veins. When arriving in the right ventricle, venous blood passed through tiny pores in the ventricular septum into the left ventricle, where it became aerated by air passing from the lungs through the pulmonary veins to the left side of the heart. Following arrival at distal sites, arterial blood disappeared, being consumed by the tissues, requiring that the liver needed to continually synthesize new blood. The heart was viewed as a sucking organ, and the peripheral pulse was deemed to result from changes in arterial tone, rather than cardiac systole. Galen's framework remained undisputed and dominated medical thought for 1,300 years, but the reintroduction of Aristotelian principles from the Islamic world into Europe (through the efforts of the Toledo School of Translators) were nurtured by the academic freedom and iconoclastic environment uniquely cultivated at the University of Padua, made possible by Venetian rebellion against papal authority. At Padua, the work of Andreas Vesalius, Realdo Colombo, Hieronymus Fabricius ab Acquapendente, and William Harvey (1543-1628) methodically destroyed Galen's model, leading to the modern concept of a closed-ended circulation. Yet, due to political forces, Harvey was ridiculed, as was James Lind, who performed the first prospective controlled trial, involving citrus fruits for scurvy (1747); it took nearly 50 years for his work to be accepted. Even the work of William Withering (1785), the father of cardiovascular pharmacology, was tarnished by professional jealously and the marketing campaign of a pharmaceutical company. Today's cardiovascular investigators should understand that major advances are routinely derided by the medical establishment for political or personal reasons; and it may take decades or centuries for important work to be accepted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38925728/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38925728</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.420>10.1016/j.jacc.2024.03.420</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38925728</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Lessons for Cardiovascular Clinical Investigators: The Tumultuous 2,500-Year Journey of Physicians Who Ignited Our Fire</dc:title>
<dc:identifier>pmid:38925728</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.420</dc:identifier>
</item>
<item>
<title>ALARA in Atrial Fibrillation: Redefining Ablation Success</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38925727/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 2;84(1):75-77. doi: 10.1016/j.jacc.2024.05.011. Epub 2024 May 22.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38925727/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38925727</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.011>10.1016/j.jacc.2024.05.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38925727</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter Hanna</dc:creator>
<dc:creator>Carlos Macias</dc:creator>
<dc:creator>Eric Buch</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>ALARA in Atrial Fibrillation: Redefining Ablation Success</dc:title>
<dc:identifier>pmid:38925727</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.011</dc:identifier>
</item>
<item>
<title>The FDA and the Cardiovascular Community</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38925726/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 2;84(1):124-129. doi: 10.1016/j.jacc.2024.05.013.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38925726/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38925726</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.013>10.1016/j.jacc.2024.05.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38925726</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Haider J Warraich</dc:creator>
<dc:creator>Robert M Califf</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The FDA and the Cardiovascular Community</dc:title>
<dc:identifier>pmid:38925726</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.013</dc:identifier>
</item>
<item>
<title>Inflammation, Colchicine, and Atherosclerotic Disease: Is Familial Mediterranean Fever an Exception That Proves the Rule?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38925725/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 2;84(1):121-123. doi: 10.1016/j.jacc.2024.04.044.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38925725/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38925725</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.044>10.1016/j.jacc.2024.04.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38925725</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Eldad Ben-Chetrit</dc:creator>
<dc:creator>Mark Nidorf</dc:creator>
<dc:creator>Rodney Falk</dc:creator>
<dc:creator>Paul M Ridker</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Inflammation, Colchicine, and Atherosclerotic Disease: Is Familial Mediterranean Fever an Exception That Proves the Rule?</dc:title>
<dc:identifier>pmid:38925725</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.044</dc:identifier>
</item>
<item>
<title>The Next Era of JACC</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38925724/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 2;84(1):118-120. doi: 10.1016/j.jacc.2024.05.023.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38925724/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38925724</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.023>10.1016/j.jacc.2024.05.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38925724</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Next Era of JACC</dc:title>
<dc:identifier>pmid:38925724</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.023</dc:identifier>
</item>
<item>
<title>The Editorship of the Journal of the American College of Cardiology: Passing the Torch</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38925723/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jul 2;84(1):115-117. doi: 10.1016/j.jacc.2024.04.045.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38925723/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38925723</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.045>10.1016/j.jacc.2024.04.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38925723</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Eugene Braunwald</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Editorship of the Journal of the American College of Cardiology: Passing the Torch</dc:title>
<dc:identifier>pmid:38925723</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.045</dc:identifier>
</item>
<item>
<title>Multiplexed single-cell characterization of alternative polyadenylation regulators</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38925112/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>Most mammalian genes have multiple polyA sites, representing a substantial source of transcript diversity regulated by the cleavage and polyadenylation (CPA) machinery. To better understand how these proteins govern polyA site choice, we introduce CPA-Perturb-seq, a multiplexed perturbation screen dataset of 42 CPA regulators with a 3' scRNA-seq readout that enables transcriptome-wide inference of polyA site usage. We develop a framework to detect perturbation-dependent changes in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 20:S0092-8674(24)00645-7. doi: 10.1016/j.cell.2024.06.005. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Most mammalian genes have multiple polyA sites, representing a substantial source of transcript diversity regulated by the cleavage and polyadenylation (CPA) machinery. To better understand how these proteins govern polyA site choice, we introduce CPA-Perturb-seq, a multiplexed perturbation screen dataset of 42 CPA regulators with a 3' scRNA-seq readout that enables transcriptome-wide inference of polyA site usage. We develop a framework to detect perturbation-dependent changes in polyadenylation and characterize modules of co-regulated polyA sites. We find groups of intronic polyA sites regulated by distinct components of the nuclear RNA life cycle, including elongation, splicing, termination, and surveillance. We train and validate a deep neural network (APARENT-Perturb) for tandem polyA site usage, delineating a cis-regulatory code that predicts perturbation response and reveals interactions between regulatory complexes. Our work highlights the potential for multiplexed single-cell perturbation screens to further our understanding of post-transcriptional regulation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38925112/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38925112</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.06.005>10.1016/j.cell.2024.06.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38925112</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Madeline H Kowalski</dc:creator>
<dc:creator>Hans-Hermann Wessels</dc:creator>
<dc:creator>Johannes Linder</dc:creator>
<dc:creator>Carol Dalgarno</dc:creator>
<dc:creator>Isabella Mascio</dc:creator>
<dc:creator>Saket Choudhary</dc:creator>
<dc:creator>Austin Hartman</dc:creator>
<dc:creator>Yuhan Hao</dc:creator>
<dc:creator>Anshul Kundaje</dc:creator>
<dc:creator>Rahul Satija</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Multiplexed single-cell characterization of alternative polyadenylation regulators</dc:title>
<dc:identifier>pmid:38925112</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.06.005</dc:identifier>
</item>
<item>
<title>Management of cardiac sarcoidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38923509/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>Cardiac sarcoidosis (CS) is a form of inflammatory cardiomyopathy associated with significant clinical complications such as high-degree atrioventricular block, ventricular tachycardia, and heart failure as well as sudden cardiac death. It is therefore important to provide an expert consensus statement summarizing the role of different available diagnostic tools and emphasizing the importance of a multidisciplinary approach. By integrating clinical information and the results of diagnostic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 26:ehae356. doi: 10.1093/eurheartj/ehae356. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiac sarcoidosis (CS) is a form of inflammatory cardiomyopathy associated with significant clinical complications such as high-degree atrioventricular block, ventricular tachycardia, and heart failure as well as sudden cardiac death. It is therefore important to provide an expert consensus statement summarizing the role of different available diagnostic tools and emphasizing the importance of a multidisciplinary approach. By integrating clinical information and the results of diagnostic tests, an accurate, validated, and timely diagnosis can be made, while alternative diagnoses can be reasonably excluded. This clinical expert consensus statement reviews the evidence on the management of different CS manifestations and provides advice to practicing clinicians in the field on the role of immunosuppression and the treatment of cardiac complications based on limited published data and the experience of international CS experts. The monitoring and risk stratification of patients with CS is also covered, while controversies and future research needs are explored.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38923509/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38923509</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae356>10.1093/eurheartj/ehae356</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38923509</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Rakesh Sharma</dc:creator>
<dc:creator>Vasileios Kouranos</dc:creator>
<dc:creator>Leslie T Cooper</dc:creator>
<dc:creator>Marco Metra</dc:creator>
<dc:creator>Arsen Ristic</dc:creator>
<dc:creator>Bettina Heidecker</dc:creator>
<dc:creator>John Baksi</dc:creator>
<dc:creator>Eleanor Wicks</dc:creator>
<dc:creator>Jose L Merino</dc:creator>
<dc:creator>Karin Klingel</dc:creator>
<dc:creator>Massimo Imazio</dc:creator>
<dc:creator>Christian de Chillou</dc:creator>
<dc:creator>Carsten Tschöpe</dc:creator>
<dc:creator>Petr Kuchynka</dc:creator>
<dc:creator>Steffen E Petersen</dc:creator>
<dc:creator>Theresa McDonagh</dc:creator>
<dc:creator>Thomas Lüscher</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Management of cardiac sarcoidosis</dc:title>
<dc:identifier>pmid:38923509</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae356</dc:identifier>
</item>
<item>
<title>Implementation of First-trimester Screening and Prevention of Preeclampsia: a Stepped Wedge Cluster-randomized Trial in Asia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38923439/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The implementation of the screen-and-prevent strategy for preterm PE is not associated with a significant reduction in the incidence of preterm PE. However, low-dose aspirin effectively reduces the incidence of preterm PE by 41% among high-risk women. The screen-and-prevent strategy for preterm PE is highly accepted by a diverse group of women from various ethnic backgrounds beyond the original population where the strategy was developed. These findings underpin the importance of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jun 26. doi: 10.1161/CIRCULATIONAHA.124.069907. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: This trial aimed to assess the efficacy, acceptability and safety of a first-trimester screen-and-prevent strategy for preterm preeclampsia (PE) in Asia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Between 1<sup>st</sup> August 2019 and 28<sup>th</sup> February 2022, this multicenter stepped wedge cluster randomized trial included maternity/diagnostic units from ten regions in Asia. The trial started with a period where all recruiting centers provided routine antenatal care without study-related intervention. At regular six-week intervals, one cluster was randomized to transit from non-intervention phase to intervention phase. In the intervention phase, women underwent first-trimester screening for preterm PE using a Bayes theorem-based triple-test. High-risk women, with adjusted risk for preterm PE ≥ 1 in 100, received low-dose aspirin from &lt;16 weeks until 36 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall, 88.04% (42,897/48,725) of women agreed to undergo first-trimester screening for preterm PE. Among those identified as high-risk in the intervention phase, 82.39% (2,919/3,543) received aspirin prophylaxis. There was no significant difference in the incidence of preterm PE between the intervention and non-intervention phases (adjusted odds ratio [aOR] 1.59; 95% confidence interval [CI] 0.91 to 2.77). However, among high-risk women in the intervention phase, aspirin prophylaxis was significantly associated with a 41% reduction in the incidence of preterm PE (aOR 0.59; 95%CI 0.37 to 0.92). Additionally, it correlated with 54%, 55% and 64% reduction in the incidence of PE with delivery at &lt;34 weeks (aOR 0.46; 95%CI 0.23 to 0.93), spontaneous preterm birth &lt;34 weeks (aOR 0.45; 95%CI 0.22 to 0.92) and perinatal death (aOR 0.34; 95%CI 0.12 to 0.91), respectively. There was no significant between-group difference in the incidence of aspirin-related severe adverse events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The implementation of the screen-and-prevent strategy for preterm PE is not associated with a significant reduction in the incidence of preterm PE. However, low-dose aspirin effectively reduces the incidence of preterm PE by 41% among high-risk women. The screen-and-prevent strategy for preterm PE is highly accepted by a diverse group of women from various ethnic backgrounds beyond the original population where the strategy was developed. These findings underpin the importance of the widespread implementation of the screen-and-prevent strategy for preterm PE on a global scale.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38923439/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38923439</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069907>10.1161/CIRCULATIONAHA.124.069907</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38923439</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Long Nguyen-Hoang</dc:creator>
<dc:creator>Linh Thuy Dinh</dc:creator>
<dc:creator>Angela S T Tai</dc:creator>
<dc:creator>Duy-Anh Nguyen</dc:creator>
<dc:creator>Ritsuko K Pooh</dc:creator>
<dc:creator>Arihiro Shiozaki</dc:creator>
<dc:creator>Mingming Zheng</dc:creator>
<dc:creator>Yali Hu</dc:creator>
<dc:creator>Bin Li</dc:creator>
<dc:creator>Raden Aditya Kusuma</dc:creator>
<dc:creator>Piengbulan Yapan</dc:creator>
<dc:creator>Arundhati Gosavi</dc:creator>
<dc:creator>Mayumi Kaneko</dc:creator>
<dc:creator>Suchaya Luewan</dc:creator>
<dc:creator>Tung-Yao Chang</dc:creator>
<dc:creator>Noppadol Chaiyasit</dc:creator>
<dc:creator>Tongta Nanthakomon</dc:creator>
<dc:creator>Huishu Liu</dc:creator>
<dc:creator>Steven W Shaw</dc:creator>
<dc:creator>Wing Cheong Leung</dc:creator>
<dc:creator>Zaleha Abdullah Mahdy</dc:creator>
<dc:creator>Angela Aguilar</dc:creator>
<dc:creator>Hillary H Y Leung</dc:creator>
<dc:creator>Nikki M W Lee</dc:creator>
<dc:creator>So Ling Lau</dc:creator>
<dc:creator>Isabella Y M Wah</dc:creator>
<dc:creator>Xiaohong Lu</dc:creator>
<dc:creator>Daljit S Sahota</dc:creator>
<dc:creator>Marc K C Chong</dc:creator>
<dc:creator>Liona C Poon</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Implementation of First-trimester Screening and Prevention of Preeclampsia: a Stepped Wedge Cluster-randomized Trial in Asia</dc:title>
<dc:identifier>pmid:38923439</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069907</dc:identifier>
</item>
<item>
<title>Routine Stress Testing After PCI in Patients With and Without Acute Coronary Syndrome: A Secondary Analysis of the POST-PCI Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38922632/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION AND RELEVANCE: Despite being at higher risk for adverse clinical events in the first year after PCI than patients without ACS, patients with ACS who had undergone high-risk PCI did not derive incremental benefit from routine surveillance stress testing at 12 months compared with standard care alone during follow-up.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jun 26. doi: 10.1001/jamacardio.2024.1556. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The appropriate follow-up surveillance strategy for patients with acute coronary syndrome (ACS) who have undergone percutaneous coronary intervention (PCI) remains unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess clinical outcomes in patients with and without ACS who have undergone high-risk PCI according to a follow-up strategy of routine stress testing at 12 months after PCI vs standard care alone.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The POST-PCI (Pragmatic Trial Comparing Symptom-Oriented vs Routine Stress Testing in High-Risk Patients Undergoing Percutaneous Coronary Intervention) trial was a randomized clinical trial that compared follow-up strategies of routine functional testing vs standard care alone 12 months after high-risk PCI. Patients were categorized as presenting with or without ACS. Patients were enrolled in the trial from November 2017 through September 2019, and patients were randomized from 11 sites in South Korea; data analysis was performed in 2022.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Patients categorized as presenting with or without ACS were randomized to either a routine functional testing or standard care alone follow-up strategy 12 months after high-risk PCI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of death from any cause, myocardial infarction, or hospitalization for unstable angina at 2 years following randomization. Kaplan-Meier event rates through 2 years and Cox model hazard ratios (HRs) were generated, and interactions were tested.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 1706 included patients, 350 patients (20.5%) were female, and the mean (SD) patient age was 64.7 (10.3) years. In total, 526 patients (30.8%) presented with ACS. Compared with those without ACS, patients with ACS had a 55% greater risk of the primary outcome (HR, 1.55; 95% CI, 1.03-2.33; P = .03) due to higher event rates in the first year. The 2-year incidences of the primary outcome were similar between strategies of routine functional testing or standard care alone in patients with ACS (functional testing: 16 of 251 [6.6%]; standard care: 23 of 275 [8.5%]; HR, 0.76; 95% CI, 0.40-1.44; P = .39) and in patients without ACS (functional testing: 30 of 598 [5.1%]; standard care: 28 of 582 [4.9%]; HR, 1.04; 95% CI, 0.62-1.74; P = .88) (P for interaction for ACS = .45). Although a landmark analysis suggested that the rates of invasive angiography and repeat revascularization were higher after 1 year in the routine functional testing group, the formal interactions between ACS status and either invasive angiography or repeat revascularization were not significant.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION AND RELEVANCE: Despite being at higher risk for adverse clinical events in the first year after PCI than patients without ACS, patients with ACS who had undergone high-risk PCI did not derive incremental benefit from routine surveillance stress testing at 12 months compared with standard care alone during follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03217877.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38922632/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38922632</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1556>10.1001/jamacardio.2024.1556</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38922632</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Jinho Lee</dc:creator>
<dc:creator>Do-Yoon Kang</dc:creator>
<dc:creator>Hoyun Kim</dc:creator>
<dc:creator>Yeonwoo Choi</dc:creator>
<dc:creator>Sangyong Jo</dc:creator>
<dc:creator>Jung-Min Ahn</dc:creator>
<dc:creator>Seonok Kim</dc:creator>
<dc:creator>Yong-Hoon Yoon</dc:creator>
<dc:creator>Seung-Ho Hur</dc:creator>
<dc:creator>Cheol Hyun Lee</dc:creator>
<dc:creator>Won-Jang Kim</dc:creator>
<dc:creator>Se Hun Kang</dc:creator>
<dc:creator>Chul Soo Park</dc:creator>
<dc:creator>Bong-Ki Lee</dc:creator>
<dc:creator>Jung-Won Suh</dc:creator>
<dc:creator>Jae Woong Choi</dc:creator>
<dc:creator>Kee-Sik Kim</dc:creator>
<dc:creator>Su Nam Lee</dc:creator>
<dc:creator>Seung-Jung Park</dc:creator>
<dc:creator>Duk-Woo Park</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Routine Stress Testing After PCI in Patients With and Without Acute Coronary Syndrome: A Secondary Analysis of the POST-PCI Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38922632</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1556</dc:identifier>
</item>
<item>
<title>Rare and Common Genetic Variation Underlying Atrial Fibrillation Risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38922602/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240628021302&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Rare and common genetic variation were associated with an increased risk of AF. The findings provide insights into the genetic underpinnings of AF and may aid in future genetic risk stratification.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Jun 26. doi: 10.1001/jamacardio.2024.1528. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Atrial fibrillation (AF) has a substantial genetic component. The importance of polygenic risk is well established, while the contribution of rare variants to disease risk warrants characterization in large cohorts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To identify rare predicted loss-of-function (pLOF) variants associated with AF and elucidate their role in risk of AF, cardiomyopathy (CM), and heart failure (HF) in combination with a polygenic risk score (PRS).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a genetic association and nested case-control study. The impact of rare pLOF variants was evaluated on the risk of incident AF. HF and CM were assessed in cause-specific Cox regressions. End of follow-up was July 1, 2022. Data were analyzed from January to October 2023. The UK Biobank enrolled 502 480 individuals aged 40 to 69 years at inclusion in the United Kingdom between March 13, 2006, and October 1, 2010. UK residents of European ancestry were included. Individuals with prior diagnosis of AF were excluded from analyses of incident AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Rare pLOF variants and an AF PRS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Risk of AF and incident HF or CM prior to and subsequent to AF diagnosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 403 990 individuals (218 489 [54.1%] female) with a median (IQR) age of 58 (51-63) years were included; 24 447 were diagnosed with incident AF over a median (IQR) follow-up period of 13.3 (12.4-14.0) years. Rare pLOF variants in 6 genes (TTN, RPL3L, PKP2, CTNNA3, KDM5B, and C10orf71) were associated with AF. Of these, TTN, RPL3L, PKP2, CTNNA3, and KDM5B replicated in an external cohort. Combined with high PRS, rare pLOF variants conferred an odds ratio of 7.08 (95% CI, 6.03-8.28) for AF. Carriers with high PRS also had a substantial 10-year risk of AF (16% in female individuals and 24% in male individuals older than 60 years). Rare pLOF variants were associated with increased risk of CM both prior to AF (hazard ratio [HR], 3.13; 95% CI, 2.24-4.36) and subsequent to AF (HR, 2.98; 95% CI, 1.89-4.69).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Rare and common genetic variation were associated with an increased risk of AF. The findings provide insights into the genetic underpinnings of AF and may aid in future genetic risk stratification.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38922602/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240628021302&v=2.18.0.post9+e462414">38922602</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.1528>10.1001/jamacardio.2024.1528</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38922602</guid>
<pubDate>Wed, 26 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Oliver B Vad</dc:creator>
<dc:creator>Laia M Monfort</dc:creator>
<dc:creator>Christian Paludan-Müller</dc:creator>
<dc:creator>Konstantin Kahnert</dc:creator>
<dc:creator>Søren Z Diederichsen</dc:creator>
<dc:creator>Laura Andreasen</dc:creator>
<dc:creator>Luca A Lotta</dc:creator>
<dc:creator>Jonas B Nielsen</dc:creator>
<dc:creator>Alicia Lundby</dc:creator>
<dc:creator>Jesper H Svendsen</dc:creator>
<dc:creator>Morten S Olesen</dc:creator>
<dc:creator>Geisinger MyCode Community Health Initiative and the Regeneron Genetics Center (RGC) Research Team</dc:creator>
<dc:date>2024-06-26</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Rare and Common Genetic Variation Underlying Atrial Fibrillation Risk</dc:title>
<dc:identifier>pmid:38922602</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.1528</dc:identifier>
</item>





























</channel>
</rss>